Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis

被引:3
|
作者
Liu, Xin [1 ]
Li, Su [2 ]
Ke, Liyuan [2 ]
Cui, Hongxia [2 ]
机构
[1] China Med Univ, Canc Hosp, Liaoning Canc Hosp & Inst, Dept Colorectal Surg, Shenyang, Peoples R China
[2] China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Pharm, Shenyang, Peoples R China
关键词
Rheumatologic preexisting autoimmune diseases; Immune checkpoint inhibitors; Immune-related adverse events; Meta-analysis; ADVERSE EVENTS; ADVANCED MELANOMA; IPILIMUMAB; NIVOLUMAB; SAFETY; EFFICACY; THERAPY; RISK; IMMUNOTHERAPY; ASSOCIATION;
D O I
10.1186/s12885-024-12256-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Patients with rheumatologic preexisting autoimmune disease (PAD) have not been enrolled in clinical trials of immune checkpoint inhibitors (ICIs). Therefore, the risks and benefits of ICI therapy in such patients are unclear. Herein, we investigated the safety and efficacy of ICIs in rheumatologic PAD patients through a meta-analysis.Methods The PubMed, Cochrane Library, Embase and Web of Science databases were searched for additional studies. We analyzed the following data through Stata software: incidence of total irAEs (TirAEs), rate of flares, incidence of new on-set irAEs, rate of discontinuation, objective response rate (ORR) and disease control rate (DCR).Results We identified 23 articles including 643 patients with rheumatologic PAD. The pooled incidences of TirAEs, flares and new-onset irAEs were 64% (95% CI 55%-72%), 41% (95% CI 31%-50%), and 33% (95% CI 28%-38%), respectively. In terms of severity, the incidences were 7% (95% CI 2%-14%) for Grade 3-4 flares and 12% (95% CI 9%-15%) for Grade 3-4 new-onset irAEs. Patients with RA had a greater risk of flares than patients with other rheumatologic PADs did (RR = 1.35, 95% CI 1.03-1.77). The ORR and DCR were 30% and 44%, respectively. Baseline anti-rheumatic treatment was not significantly associated with the frequency of flares (RR = 1.05, 95% CI 0.63-1.77) or the ORR (RR = 0.45, 95% CI 0.12-1.69).Conclusions Patients with rheumatologic PAD, particularly those with RA, are susceptible to relapse of their rheumatologic disease following ICI therapy. ICIs are also effective for treating rheumatologic PAD patients.Prospective register of systematic reviews (PROSPERO) number CRD 42,023,439,702.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Clinical outcomes of immune checkpoint inhibitors in patients with metastatic colorectal cancer: A systematic review with meta-analysis
    Shek, D.
    Akhuba, L.
    Read, S. A.
    Carlino, M. S.
    Nagrial, A.
    Moujaber, T.
    Gao, B.
    Ahlenstiel, G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 28 - 28
  • [22] Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
    Zhengzheng Xia
    Jianyu Zhang
    Wenjun Chen
    Haiyan Zhou
    Di Du
    Kongcai Zhu
    Hui Chen
    Jun Meng
    Jun Yang
    Infectious Diseases of Poverty, 12
  • [23] Risk Factors for Cardiotoxicity in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Systematic Review With Meta-Analysis
    Huang, Chin-Hsuan
    Abdul-Lattif, Eahab
    Azmat, Muneeba
    Chang, Yu
    Lin, Yu Shiuan
    Md, Michele Nanna
    Chi, Kuan Yu
    CIRCULATION, 2022, 146
  • [24] The negative impact of opioids on cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
    Ju, Mingguang
    Gao, Ziming
    Liu, Xiaofang
    Zhou, Heng
    Wang, Ruiying
    Zheng, Chen
    Dong, Daosong
    Zhu, Zhi
    Li, Kai
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (06) : 2699 - 2708
  • [25] Biomarkers to predict efficacy of immune checkpoint inhibitors in colorectal cancer patients: a systematic review and meta-analysis
    Yu, Hang
    Liu, Qingquan
    Wu, Keting
    Tang, Shuang
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [26] Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis
    Li, Song
    Xu, Qian
    Dai, Xin
    Zhang, Xue
    Huang, Miao
    Huang, Kai
    Shi, Duanbo
    Wang, Jian
    Liu, Lian
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (06) : 3594 - 3602
  • [27] Efficacy and Safety of Immune Checkpoint Inhibitors for Cervical Cancer: A Systematic Review and Meta-Analysis
    Zhang, Xian
    Zhan, Yuejuan
    Zhou, Yannan
    Liu, Chang
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2024, 51 (08):
  • [28] Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis
    Song Li
    Qian Xu
    Xin Dai
    Xue Zhang
    Miao Huang
    Kai Huang
    Duanbo Shi
    Jian Wang
    Lian Liu
    Annals of Surgical Oncology, 2023, 30 : 3594 - 3602
  • [29] Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
    Xu, Cheng
    Chen, Yu-Pei
    Du, Xiao-Jing
    Liu, Jin-Qi
    Huang, Cheng-Long
    Chen, Lei
    Zhou, Guan-Qun
    Li, Wen-Fei
    Mao, Yan-Ping
    Hsu, Chiun
    Liu, Qing
    Lin, Ai-Hua
    Tang, Ling-Long
    Sun, Ying
    Ma, Jun
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 363
  • [30] Efficacy and safety of immune checkpoint inhibitors in colorectal cancer: a systematic review and meta-analysis
    Zeng, Tianni
    Fang, Xiaojie
    Lu, Jinhua
    Zhong, Yazhen
    Lin, Xianlei
    Lin, Zechen
    Wang, Nan
    Jiang, Jing
    Lin, Shengyou
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2022, 37 (01) : 251 - 258